Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Warfarin inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of functional clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
| Metabolism | Hepatic metabolism primarily via CYP2C9 (major), with contributions from CYP3A4, CYP1A2, and CYP2C19. Warfarin is a racemic mixture: S-warfarin (more potent) is metabolized by CYP2C9; R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19. |
| Excretion | Renal: approximately 92% as inactive metabolites (conjugated and unconjugated); biliary/fecal: approximately 8% as minor metabolites. |
| Half-life | Terminal half-life: 40 hours (range 20–60 hours); clinical context: long half-life causes delayed onset and prolonged duration, leading to 3–5 days to steady state. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | Vd: 0.14 L/kg (range 0.11–0.2 L/kg); clinical meaning: low volume indicates high protein binding and limited tissue distribution. |
| Bioavailability | Oral: 100% (practically complete absorption). |
| Onset of Action | Oral: 24–72 hours for therapeutic INR (2–3) typically seen at 48–72 hours; IV: similar onset. |
| Duration of Action | Duration of action: 2–5 days; clinical note: effect persists 3–5 days after discontinuation due to half-life. |
| Molecular Weight | 308.33 |
Oral, 2-10 mg once daily adjusted based on INR, with a loading dose of 5-10 mg for 1-3 days in acute anticoagulation.
| Renal impairment | No dose adjustment required for renal impairment; however, warfarin is highly protein-bound and volume of distribution may decrease with severe renal impairment, requiring closer INR monitoring. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50% and monitor INR closely; Child-Pugh C: Contraindicated due to impaired synthesis of clotting factors and increased bleeding risk. |
| Pediatric use | Initial dose 0.2 mg/kg orally once daily; maintenance dose adjusted to target INR of 2.0-3.0, typically 0.1 mg/kg once daily; maximum initial dose 5 mg. |
| Geriatric use | Start with lower doses (2-5 mg orally once daily) due to increased sensitivity and risk of bleeding; monitor INR more frequently, especially at initiation and after any dose changes. |
| 1st trimester | Category X: Teratogenic effects observed in first trimester; associated with fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses). Avoid use. |
| 2nd trimester | Category X: Continued risk of fetal hemorrhage and central nervous system abnormalities; use with extreme caution only if maternal benefit outweighs risk, with strict INR monitoring. |
| 3rd trimester | Category X: Risk of fetal hemorrhage, placental abruption, and preterm labor; avoid near term (especially after 36 weeks) due to neonatal hemorrhage risk. |
Clinical note
Contraindicated in most circumstances. Warfarin is a proven human teratogen. Exposure between 6–9 weeks gestation causes Fetal Warfarin Syndrome: nasal hypoplasia, stippled epiphyses, and limb defects in approximately 5% of exposed fetuses. Any trimester exposure carries risk of fetal intracranial hemorrhage due to anticoagulation of the fetal blood. Exception: women with mechanical heart valves may require warfarin due to inadequate LMWH valve protection — this requires individualized multidisciplinary decision-making.
| Placental transfer | Warfarin crosses the placenta via passive diffusion. Fetal plasma concentrations are approximately equal to maternal concentrations due to low molecular weight and high lipid solubility. |
■ FDA Black Box Warning
Warfarin can cause major or fatal bleeding. Monitor INR regularly and adjust dose to maintain therapeutic level. Risk factors include age, renal impairment, comorbidities, and concomitant medications. Instruct patients on signs of bleeding. Concomitant use of NSAIDs, aspirin, or other anticoagulants increases bleeding risk.
| Serious Effects |
Hemorrhagic tendencies or blood dyscrasiasActive bleeding or recent hemorrhage (including GI, intracranial)Severe hepatic impairment or cirrhosisMalignant hypertensionPregnancy (especially first and third trimesters)Lactation (relative contraindication, but considered safe by many; absolute if using high doses or if infant has vitamin K deficiency)Recent or pending surgery with risk of bleedingLumbar puncture or regional anesthesiaInability to comply with monitoring
| Precautions | Hemorrhage: major or fatal bleeding; monitor INR closely, Necrosis/skin necrosis: rare, due to protein C deficiency; discontinue if suspected, Systemic atheroemboli/cholesterol emboli: purple toe syndrome, Pregnancy: can cause fetal harm; contraindicated except in high-risk mechanical valves (category X), Hepatic impairment: increased INR response, Renal impairment: increased bleeding risk, Elderly: increased sensitivity, Drug interactions: numerous (e.g., NSAIDs, antibiotics, antifungals, antiplatelets, statins, certain foods like cranberry juice, and vitamin K) |
Loading safety data…
| Breastfeeding | Warfarin is excreted into breast milk in negligible amounts and is considered compatible with breastfeeding. No adverse effects reported in breastfed infants. Monitor infant for bruising or bleeding, especially if high maternal doses. Give advice to avoid activities that may cause injury. |
| Lactation Rating | L2: Safer (limited data, no harm) |
| Teratogenic Risk | First trimester: Warfarin is associated with a characteristic embryopathy (fetal warfarin syndrome) occurring in 5-30% of exposed fetuses, including nasal hypoplasia, stippled epiphyses, and central nervous system abnormalities. Second and third trimesters: Risk of fetal hemorrhage, including intracranial bleeding, and spontaneous abortion. Use is contraindicated in pregnancy due to fetal risks; heparin or low molecular weight heparin preferred. |
| Fetal Monitoring | Maternal: International Normalized Ratio (INR) monitoring at least weekly or as needed. Fetal: Serial ultrasound to assess growth and anatomy; consider fetal echocardiography if first trimester exposure. Avoid during pregnancy unless necessary for mechanical heart valves; then use with careful INR monitoring and consider switching to heparin near term. |
| Fertility Effects | No direct effects on fertility reported. Warfarin may be used in women of childbearing potential with effective contraception counseling due to teratogenicity. |
| Food/Dietary | Foods high in vitamin K (e.g., kale, spinach, collard greens, Swiss chard, parsley, Brussels sprouts, broccoli, green tea) can antagonize warfarin effect; maintain consistent intake. Cranberry juice, grapefruit juice, and alcohol (especially binge drinking) may potentiate effect. Avoid large amounts of avocado, mango, and certain herbal supplements (e.g., ginseng, ginkgo, St. John's wort, coenzyme Q10). |
| Clinical Pearls | Monitor INR closely, especially when initiating, discontinuing, or changing doses of interacting drugs. Avoid intramuscular injections due to bleeding risk. Warfarin has a narrow therapeutic index and requires regular INR monitoring (target usually 2-3 for most indications). Consider pharmacogenetic testing for CYP2C9 and VKORC1 variants to guide dosing. Use with caution in patients with renal or hepatic impairment. Vitamin K can reverse effects; consider low-dose vitamin K for over-anticoagulation without major bleeding. |
| Patient Advice | Take warfarin exactly as prescribed, typically once daily at the same time. · Avoid making significant changes to your diet, especially foods high in vitamin K (e.g., leafy greens, broccoli, Brussels sprouts). · Do not start or stop any other medications, including over-the-counter drugs, herbal supplements, or vitamins, without consulting your doctor. · Report any unusual bleeding or bruising, dark/tarry stools, blood in urine, or severe headache to your healthcare provider. · Use a soft toothbrush and electric razor to minimize bleeding risk. · Carry a medical ID or card indicating you are taking warfarin. · Keep all appointments for INR blood tests. · Avoid alcohol consumption or limit to minimal amounts. · If a dose is missed, take it as soon as remembered on the same day; do not double the next day's dose. Contact doctor if unsure. |